Table 2.
Variables associated with drug retention.
| Variables | p | HR | 95%CI |
|---|---|---|---|
| Gender | 0.241 | ||
| CD | 0.587 | ||
| CD location | 0.697 | ||
| CD behaviour | 0.212 | ||
| Age at diagnosis | 0.477 | ||
| Age at start of infliximab | 0.537 | ||
| Duration from infliximab initiation until first detectable ATI | 0.777 | ||
| UC extension | 0.552 | ||
| Perianal fistulising disease | 1.000 | ||
| Ileocolonic resection prior to first detectable ATI | 0.623 | ||
| Concomitant IMM at first detectable ATI | 0.735 | ||
| Anti-TNF naive | 0.164 | ||
| Smoking ever | 0.485 | ||
| Infliximab dosing other than 5mg/Kg q8w at first detectable ATI | 0.440 | ||
| Type of first intervention after first detectable ATI | 0.408 | ||
| Titer of first detectable ATI | 0.016 | 0.89 | 0.82–0.98 |
| Reactive TDM | 0.151 | ||
| Center | 0.431 | ||
| Infliximab concentration at first detectable ATI | 0.847 | ||
| Undetectable infliximab concentration at first detectable ATI | 0.718 |
IBD: inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis; HR: hazard ratio; CI: confidence interval; TDM: therapeutic drug monitoring; IMM: immunomodulators; TNF: tumor necrosis factor; ATI: antibodies to infliximab; w: week.